Movement Alert|Zoetis Falls 4.04% in Regular Trading, USDA approval for three-disease chicken vaccine failed to lift shares

Market Focus
11/19

On November 19, Zoetis fell 4.04% in Regular Trading, trading at $82.2101 per share with turnover of $28.1379 million.

The clearest recent catalyst was the company’s announcement that the US Department of Agriculture licensed Poulvac Procerta HVT-ND-ILT, a vector vaccine for chickens designed to protect against Marek's disease, Newcastle disease, and infectious laryngotracheitis. However, the approval did not improve market sentiment, with the stock also indicated lower earlier in the session.

Background factors may have limited the positive read-through. Zoetis reported September-quarter revenue of $2.39 billion, down 1% year over year, although adjusted EPS of $1.75 topped expectations and full-year revenue guidance was raised to $9.22 billion to $9.32 billion. Even with the product approval, investors appear to remain cautious on the durability of growth.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10